APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prevent Meningitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prevent Meningitis Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025208 pages

Choose your research edition.

Industry ResearchPrevent Meningitis Vaccine Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Prevent Meningitis Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Prevent Meningitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prevent Meningitis Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Prevent Meningitis Vaccine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Prevent Meningitis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prevent Meningitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prevent Meningitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prevent Meningitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prevent Meningitis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prevent Meningitis Vaccine market include GSK, China National Biotec Group, Zhejiang Tianyuan, Sanofi Pasteur, Novartis, Merck, Tianjin CanSino Biotechnology, Pfizer and Hualan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prevent Meningitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prevent Meningitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prevent Meningitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prevent Meningitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Prevent Meningitis Vaccine Segment by Company

GSK

China National Biotec Group

Zhejiang Tianyuan

Sanofi Pasteur

Novartis

Merck

Tianjin CanSino Biotechnology

Pfizer

Hualan Bio

Beijing Tiantan Biological

Baxter International

Zhifei

Wyeth Pharmaceuticals, Inc

Walvax

Serum Institute of India

JN International Medical Corporation

CSL Behring

Bio-Med

Prevent Meningitis Vaccine Segment by Type

Meningococcal AC Vaccine

Meningococcal A Vaccine

Meningococcal B Vaccine (MenB)

Meningococcal Conjugate Vaccine (MenaCWY)

Prevent Meningitis Vaccine Segment by Application

Baby

Teenager

Child

Others

Prevent Meningitis Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Prevent Meningitis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prevent Meningitis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prevent Meningitis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Prevent Meningitis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prevent Meningitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prevent Meningitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prevent Meningitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prevent Meningitis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prevent Meningitis Vaccine industry.

Chapter 3: Detailed analysis of Prevent Meningitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prevent Meningitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prevent Meningitis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prevent Meningitis Vaccine Industry Trends Table 2. Prevent Meningitis Vaccine Industry Drivers Table 3. Prevent Meningitis Vaccine Industry Opportunities and Challenges Table 4. Prevent Meningitis Vaccine Industry Restraints Table 5. Global Prevent Meningitis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prevent Meningitis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Prevent Meningitis Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Prevent Meningitis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Prevent Meningitis Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Prevent Meningitis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prevent Meningitis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Prevent Meningitis Vaccine Company, Product Type & Application Table 13. Global Prevent Meningitis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prevent Meningitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Meningococcal AC Vaccine Table 18. Significant Companies of Meningococcal A Vaccine Table 19. Significant Companies of Meningococcal B Vaccine (MenB) Table 20. Significant Companies of Meningococcal Conjugate Vaccine (MenaCWY) Table 21. Global Prevent Meningitis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Prevent Meningitis Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Prevent Meningitis Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Prevent Meningitis Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Prevent Meningitis Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Prevent Meningitis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Prevent Meningitis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Prevent Meningitis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Prevent Meningitis Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Prevent Meningitis Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Baby Table 32. Significant Companies of Teenager Table 33. Significant Companies of Child Table 34. Significant Companies of Others Table 35. Global Prevent Meningitis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Prevent Meningitis Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Prevent Meningitis Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Prevent Meningitis Vaccine Sales Volume Share by Application (2021-2026) Table 39. Global Prevent Meningitis Vaccine Sales Volume Share by Application (2027-2032) Table 40. Global Prevent Meningitis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Prevent Meningitis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Prevent Meningitis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Prevent Meningitis Vaccine Sales Value Share by Application (2021-2026) Table 44. Global Prevent Meningitis Vaccine Sales Value Share by Application (2027-2032) Table 45. Global Prevent Meningitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Prevent Meningitis Vaccine Sales by Region (2021-2026) & (K Units) Table 47. Global Prevent Meningitis Vaccine Sales Market Share by Region (2021-2026) Table 48. Global Prevent Meningitis Vaccine Sales by Region (2027-2032) & (K Units) Table 49. Global Prevent Meningitis Vaccine Sales Market Share by Region (2027-2032) Table 50. Global Prevent Meningitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Prevent Meningitis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Prevent Meningitis Vaccine Sales Value Share by Region (2021-2026) Table 53. Global Prevent Meningitis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Prevent Meningitis Vaccine Sales Value Share by Region (2027-2032) Table 55. Global Prevent Meningitis Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Prevent Meningitis Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Prevent Meningitis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Prevent Meningitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Prevent Meningitis Vaccine Sales by Country (2021-2026) & (K Units) Table 60. Global Prevent Meningitis Vaccine Sales Market Share by Country (2021-2026) Table 61. Global Prevent Meningitis Vaccine Sales by Country (2027-2032) & (K Units) Table 62. Global Prevent Meningitis Vaccine Sales Market Share by Country (2027-2032) Table 63. Global Prevent Meningitis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Prevent Meningitis Vaccine Sales Value Market Share by Country (2021-2026) Table 65. Global Prevent Meningitis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Prevent Meningitis Vaccine Sales Value Market Share by Country (2027-2032) Table 67. GSK Company Information Table 68. GSK Business Overview Table 69. GSK Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. GSK Prevent Meningitis Vaccine Product Portfolio Table 71. GSK Recent Development Table 72. China National Biotec Group Company Information Table 73. China National Biotec Group Business Overview Table 74. China National Biotec Group Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. China National Biotec Group Prevent Meningitis Vaccine Product Portfolio Table 76. China National Biotec Group Recent Development Table 77. Zhejiang Tianyuan Company Information Table 78. Zhejiang Tianyuan Business Overview Table 79. Zhejiang Tianyuan Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Zhejiang Tianyuan Prevent Meningitis Vaccine Product Portfolio Table 81. Zhejiang Tianyuan Recent Development Table 82. Sanofi Pasteur Company Information Table 83. Sanofi Pasteur Business Overview Table 84. Sanofi Pasteur Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sanofi Pasteur Prevent Meningitis Vaccine Product Portfolio Table 86. Sanofi Pasteur Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Novartis Prevent Meningitis Vaccine Product Portfolio Table 91. Novartis Recent Development Table 92. Merck Company Information Table 93. Merck Business Overview Table 94. Merck Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Merck Prevent Meningitis Vaccine Product Portfolio Table 96. Merck Recent Development Table 97. Tianjin CanSino Biotechnology Company Information Table 98. Tianjin CanSino Biotechnology Business Overview Table 99. Tianjin CanSino Biotechnology Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Tianjin CanSino Biotechnology Prevent Meningitis Vaccine Product Portfolio Table 101. Tianjin CanSino Biotechnology Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pfizer Prevent Meningitis Vaccine Product Portfolio Table 106. Pfizer Recent Development Table 107. Hualan Bio Company Information Table 108. Hualan Bio Business Overview Table 109. Hualan Bio Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Hualan Bio Prevent Meningitis Vaccine Product Portfolio Table 111. Hualan Bio Recent Development Table 112. Beijing Tiantan Biological Company Information Table 113. Beijing Tiantan Biological Business Overview Table 114. Beijing Tiantan Biological Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Beijing Tiantan Biological Prevent Meningitis Vaccine Product Portfolio Table 116. Beijing Tiantan Biological Recent Development Table 117. Baxter International Company Information Table 118. Baxter International Business Overview Table 119. Baxter International Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Baxter International Prevent Meningitis Vaccine Product Portfolio Table 121. Baxter International Recent Development Table 122. Zhifei Company Information Table 123. Zhifei Business Overview Table 124. Zhifei Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Zhifei Prevent Meningitis Vaccine Product Portfolio Table 126. Zhifei Recent Development Table 127. Wyeth Pharmaceuticals, Inc Company Information Table 128. Wyeth Pharmaceuticals, Inc Business Overview Table 129. Wyeth Pharmaceuticals, Inc Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Wyeth Pharmaceuticals, Inc Prevent Meningitis Vaccine Product Portfolio Table 131. Wyeth Pharmaceuticals, Inc Recent Development Table 132. Walvax Company Information Table 133. Walvax Business Overview Table 134. Walvax Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Walvax Prevent Meningitis Vaccine Product Portfolio Table 136. Walvax Recent Development Table 137. Serum Institute of India Company Information Table 138. Serum Institute of India Business Overview Table 139. Serum Institute of India Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Serum Institute of India Prevent Meningitis Vaccine Product Portfolio Table 141. Serum Institute of India Recent Development Table 142. JN International Medical Corporation Company Information Table 143. JN International Medical Corporation Business Overview Table 144. JN International Medical Corporation Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. JN International Medical Corporation Prevent Meningitis Vaccine Product Portfolio Table 146. JN International Medical Corporation Recent Development Table 147. CSL Behring Company Information Table 148. CSL Behring Business Overview Table 149. CSL Behring Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. CSL Behring Prevent Meningitis Vaccine Product Portfolio Table 151. CSL Behring Recent Development Table 152. Bio-Med Company Information Table 153. Bio-Med Business Overview Table 154. Bio-Med Prevent Meningitis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Bio-Med Prevent Meningitis Vaccine Product Portfolio Table 156. Bio-Med Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Prevent Meningitis Vaccine Distributors List Table 160. Prevent Meningitis Vaccine Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Prevent Meningitis Vaccine Product Image Figure 2. Global Prevent Meningitis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prevent Meningitis Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Prevent Meningitis Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Prevent Meningitis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Meningococcal AC Vaccine Image Figure 10. Meningococcal A Vaccine Image Figure 11. Meningococcal B Vaccine (MenB) Image Figure 12. Meningococcal Conjugate Vaccine (MenaCWY) Image Figure 13. Global Prevent Meningitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Prevent Meningitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Prevent Meningitis Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Prevent Meningitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Prevent Meningitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Prevent Meningitis Vaccine Sales Value Share by Type (2021-2032) Figure 19. Baby Image Figure 20. Teenager Image Figure 21. Child Image Figure 22. Others Image Figure 23. Global Prevent Meningitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Prevent Meningitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Prevent Meningitis Vaccine Sales Volume Share by Application (2021-2032) Figure 26. Global Prevent Meningitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Prevent Meningitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Prevent Meningitis Vaccine Sales Value Share by Application (2021-2032) Figure 29. Global Prevent Meningitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Prevent Meningitis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Prevent Meningitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Prevent Meningitis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. North America Prevent Meningitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Prevent Meningitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Prevent Meningitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. South America Prevent Meningitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Prevent Meningitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Prevent Meningitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Prevent Meningitis Vaccine Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Prevent Meningitis Vaccine Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Meningococcal AC Vaccine
  • Meningococcal A Vaccine
  • Meningococcal B Vaccine (MenB)
  • Meningococcal Conjugate Vaccine (MenaCWY)
Applications
  • Baby
  • Teenager
  • Child
  • Others
Companies covered
  • GSK
  • China National Biotec Group
  • Zhejiang Tianyuan
  • Sanofi Pasteur
  • Novartis
  • Merck
  • Tianjin CanSino Biotechnology
  • Pfizer
  • Hualan Bio
  • Beijing Tiantan Biological
  • Baxter International
  • Zhifei
  • Wyeth Pharmaceuticals, Inc
  • Walvax
  • Serum Institute of India
  • JN International Medical Corporation
  • CSL Behring
  • Bio-Med

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prevent Meningitis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Prevent Meningitis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Prevent Meningitis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prevent Meningitis Vaccine Market Dynamics
  1. 2.1 Prevent Meningitis Vaccine Industry Trends
  2. 2.2 Prevent Meningitis Vaccine Industry Drivers
  3. 2.3 Prevent Meningitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Prevent Meningitis Vaccine Industry Restraints
3 Prevent Meningitis Vaccine Market by Company
  1. 3.1 Global Prevent Meningitis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Prevent Meningitis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Prevent Meningitis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Prevent Meningitis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Prevent Meningitis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Prevent Meningitis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Prevent Meningitis Vaccine Company Product Type and Application
  8. 3.8 Global Prevent Meningitis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prevent Meningitis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prevent Meningitis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prevent Meningitis Vaccine Market by Type
  1. 4.1 Prevent Meningitis Vaccine Type Introduction
  2. 4.1.1 Meningococcal AC Vaccine
  3. 4.1.2 Meningococcal A Vaccine
  4. 4.1.3 Meningococcal B Vaccine (MenB)
  5. 4.1.4 Meningococcal Conjugate Vaccine (MenaCWY)
  6. 4.2 Global Prevent Meningitis Vaccine Sales Volume by Type
  7. 4.2.1 Global Prevent Meningitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Prevent Meningitis Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Prevent Meningitis Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Prevent Meningitis Vaccine Sales Value by Type
  11. 4.3.1 Global Prevent Meningitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Prevent Meningitis Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Prevent Meningitis Vaccine Sales Value Share by Type (2021-2032)
5 Prevent Meningitis Vaccine Market by Application
  1. 5.1 Prevent Meningitis Vaccine Application Introduction
  2. 5.1.1 Baby
  3. 5.1.2 Teenager
  4. 5.1.3 Child
  5. 5.1.4 Others
  6. 5.2 Global Prevent Meningitis Vaccine Sales Volume by Application
  7. 5.2.1 Global Prevent Meningitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Prevent Meningitis Vaccine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Prevent Meningitis Vaccine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Prevent Meningitis Vaccine Sales Value by Application
  11. 5.3.1 Global Prevent Meningitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Prevent Meningitis Vaccine Sales Value by Application (2021-2032)
  13. 5.3.3 Global Prevent Meningitis Vaccine Sales Value Share by Application (2021-2032)
6 Prevent Meningitis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Prevent Meningitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prevent Meningitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Prevent Meningitis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Prevent Meningitis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Prevent Meningitis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prevent Meningitis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prevent Meningitis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prevent Meningitis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Prevent Meningitis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prevent Meningitis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Prevent Meningitis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prevent Meningitis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Prevent Meningitis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prevent Meningitis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prevent Meningitis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prevent Meningitis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Prevent Meningitis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prevent Meningitis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prevent Meningitis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Prevent Meningitis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Prevent Meningitis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prevent Meningitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prevent Meningitis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Prevent Meningitis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Prevent Meningitis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Prevent Meningitis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prevent Meningitis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prevent Meningitis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prevent Meningitis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prevent Meningitis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prevent Meningitis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Prevent Meningitis Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 China National Biotec Group
  8. 8.2.1 China National Biotec Group Company Information
  9. 8.2.2 China National Biotec Group Business Overview
  10. 8.2.3 China National Biotec Group Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China National Biotec Group Prevent Meningitis Vaccine Product Portfolio
  12. 8.2.5 China National Biotec Group Recent Developments
  13. 8.3 Zhejiang Tianyuan
  14. 8.3.1 Zhejiang Tianyuan Company Information
  15. 8.3.2 Zhejiang Tianyuan Business Overview
  16. 8.3.3 Zhejiang Tianyuan Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zhejiang Tianyuan Prevent Meningitis Vaccine Product Portfolio
  18. 8.3.5 Zhejiang Tianyuan Recent Developments
  19. 8.4 Sanofi Pasteur
  20. 8.4.1 Sanofi Pasteur Company Information
  21. 8.4.2 Sanofi Pasteur Business Overview
  22. 8.4.3 Sanofi Pasteur Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Pasteur Prevent Meningitis Vaccine Product Portfolio
  24. 8.4.5 Sanofi Pasteur Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Prevent Meningitis Vaccine Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Prevent Meningitis Vaccine Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Tianjin CanSino Biotechnology
  38. 8.7.1 Tianjin CanSino Biotechnology Company Information
  39. 8.7.2 Tianjin CanSino Biotechnology Business Overview
  40. 8.7.3 Tianjin CanSino Biotechnology Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Tianjin CanSino Biotechnology Prevent Meningitis Vaccine Product Portfolio
  42. 8.7.5 Tianjin CanSino Biotechnology Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Prevent Meningitis Vaccine Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hualan Bio
  50. 8.9.1 Hualan Bio Company Information
  51. 8.9.2 Hualan Bio Business Overview
  52. 8.9.3 Hualan Bio Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Bio Prevent Meningitis Vaccine Product Portfolio
  54. 8.9.5 Hualan Bio Recent Developments
  55. 8.10 Beijing Tiantan Biological
  56. 8.10.1 Beijing Tiantan Biological Company Information
  57. 8.10.2 Beijing Tiantan Biological Business Overview
  58. 8.10.3 Beijing Tiantan Biological Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Tiantan Biological Prevent Meningitis Vaccine Product Portfolio
  60. 8.10.5 Beijing Tiantan Biological Recent Developments
  61. 8.11 Baxter International
  62. 8.11.1 Baxter International Company Information
  63. 8.11.2 Baxter International Business Overview
  64. 8.11.3 Baxter International Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Baxter International Prevent Meningitis Vaccine Product Portfolio
  66. 8.11.5 Baxter International Recent Developments
  67. 8.12 Zhifei
  68. 8.12.1 Zhifei Company Information
  69. 8.12.2 Zhifei Business Overview
  70. 8.12.3 Zhifei Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhifei Prevent Meningitis Vaccine Product Portfolio
  72. 8.12.5 Zhifei Recent Developments
  73. 8.13 Wyeth Pharmaceuticals, Inc
  74. 8.13.1 Wyeth Pharmaceuticals, Inc Company Information
  75. 8.13.2 Wyeth Pharmaceuticals, Inc Business Overview
  76. 8.13.3 Wyeth Pharmaceuticals, Inc Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Wyeth Pharmaceuticals, Inc Prevent Meningitis Vaccine Product Portfolio
  78. 8.13.5 Wyeth Pharmaceuticals, Inc Recent Developments
  79. 8.14 Walvax
  80. 8.14.1 Walvax Company Information
  81. 8.14.2 Walvax Business Overview
  82. 8.14.3 Walvax Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Walvax Prevent Meningitis Vaccine Product Portfolio
  84. 8.14.5 Walvax Recent Developments
  85. 8.15 Serum Institute of India
  86. 8.15.1 Serum Institute of India Company Information
  87. 8.15.2 Serum Institute of India Business Overview
  88. 8.15.3 Serum Institute of India Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Serum Institute of India Prevent Meningitis Vaccine Product Portfolio
  90. 8.15.5 Serum Institute of India Recent Developments
  91. 8.16 JN International Medical Corporation
  92. 8.16.1 JN International Medical Corporation Company Information
  93. 8.16.2 JN International Medical Corporation Business Overview
  94. 8.16.3 JN International Medical Corporation Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 JN International Medical Corporation Prevent Meningitis Vaccine Product Portfolio
  96. 8.16.5 JN International Medical Corporation Recent Developments
  97. 8.17 CSL Behring
  98. 8.17.1 CSL Behring Company Information
  99. 8.17.2 CSL Behring Business Overview
  100. 8.17.3 CSL Behring Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 CSL Behring Prevent Meningitis Vaccine Product Portfolio
  102. 8.17.5 CSL Behring Recent Developments
  103. 8.18 Bio-Med
  104. 8.18.1 Bio-Med Company Information
  105. 8.18.2 Bio-Med Business Overview
  106. 8.18.3 Bio-Med Prevent Meningitis Vaccine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bio-Med Prevent Meningitis Vaccine Product Portfolio
  108. 8.18.5 Bio-Med Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prevent Meningitis Vaccine Value Chain Analysis
  2. 9.1.1 Prevent Meningitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prevent Meningitis Vaccine Sales Mode & Process
  6. 9.2 Prevent Meningitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prevent Meningitis Vaccine Distributors
  9. 9.2.3 Prevent Meningitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst